Innospec Inc.
NASDAQ:IOSPChemicals - Specialty
+$0.08 today
- Market cap
- $1.94B
- Beta
- 0.91
- P/E (TTM)
- 18.0
- EPS (TTM)
- $4.61
- Dividend yield
- 2.15%
Volume 0.23M
Average 0.24M
IOSP EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Innospec Inc.NASDAQ: IOSP
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA growth accelerates
Q2 FY2026 EBITDA of $47.8M rose 3.7% year over year, ahead of the -12.7% change in trailing-twelve-month EBITDA. Sequentially, it fell 4.0% from the prior quarter. Over 3 fiscal years it compounded at -7.0% a year.
Context
- EBITDA amounted to 10.2% of revenue in FY2025, down 2.0 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of $205.52M (+13.1%) for the fiscal year ending Dec 2026, a step up from the -19.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $47.8M-4.0% QoQ
- Last fiscal yearDec 2025
- $181.7M-19.1% YoY
- LTMJun 2026
- $181M-12.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.7% | +108.8% | +105.1 pp |
| 1 year | -19.1% | +13.1% | +32.2 pp |
| 3-year CAGR | -7.0% | +13.1% | +20.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 181.7M USD
- Year-over-year change
- -19.1%
- 4-year CAGR
- +1.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 181.7M | -19.1% |
| FY2024 | 2024-12-31 | 224.6M | +5.1% |
| FY2023 | 2023-12-31 | 213.7M | -5.4% |
| FY2022 | 2022-12-31 | 225.8M | +30.5% |
| FY2021 | 2021-12-31 | 173M | — |
EBITDA vs competitors
How IOSP compares with its peers on the latest reported figures
- IOSP's LTM Jun 2026 EBITDA of $181M is the 8th highest of the 10 companies compared; the peer median is $380M.
- Its year-over-year change of -12.7% is the 6th highest of 10, against a peer median of -5.9%.
- EBITDA amounts to 9.8% of revenue for IOSP, versus a peer median of 16.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.27B | -26.3% | -7.6% | 14.3% | |
| LTM Jun 2026 | $735.21M | -5.9% | +15.8% | 26.8% | |
| LTM Jun 2026 | $690M | -14.9% | +13.9% | 19.0% | |
| LTM Aug 2026 | $540.79M | +11.0% | +2.4% | 15.2% | |
| LTM Jun 2026 | $380M | +176.5% | — | 20.6% | |
| LTM Sep 2026 | $232.84M | +46.9% | +6.3% | 11.5% | |
| LTM Sep 2026 | $183.41M | +8.8% | +15.0% | 16.1% | |
| LTM Jun 2026 | $181M | -12.7% | -7.0% | 9.8% | |
| LTM Sep 2026 | -$39M | -113.4% | +31.7% | 0.8% | |
| LTM Mar 2026 | -$42.1M | -2075.7% | — | 38.2% | |
| Peer median (excluding IOSP) | $380M | -5.9% | +13.9% | 16.1% | |
Competitors are the stored peer set for IOSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.48B | 1.96B | 1.95B | 1.85B | 1.78B |
| Cost of Revenue | 1.05B | 1.38B | 1.36B | 1.3B | 1.29B |
| Gross Profit | 434.9M | 586.7M | 591.1M | 542.9M | 492.4M |
| Gross Margin | 29.3% | 29.9% | 30.3% | 29.4% | 27.7% |
| Research & Development | 37.4M | 38.7M | 41.7M | 47.8M | 51M |
| Selling, General & Admin | 267.2M | 360.7M | 387.8M | 314M | 285.1M |
| Operating Expenses | 302.8M | 399.4M | 429.5M | 365M | 336.1M |
| Depreciation & Amortization | 42.7M | 40.1M | 39.3M | 43.5M | 43.6M |
| EBITDA | 173M | 225.8M | 213.7M | 224.6M | 181.7M |
| EBITDA Margin | 11.7% | 11.5% | 11.0% | 12.2% | 10.2% |
| Operating Income | 132.1M | 187.3M | 161.6M | 177.9M | 156.3M |
| Operating Margin | 8.9% | 9.5% | 8.3% | 9.6% | 8.8% |
| Interest Income | 0 | 0 | 0 | 0 | 9.2M |
| Interest Expense | 1.5M | 1.1M | 0 | 0 | 0 |
| Other Income / Expenses | 2.3M | (2.7M) | 12.8M | (136.7M) | (18.2M) |
| Income Before Tax | 134.4M | 184.6M | 174.4M | 41.2M | 138.1M |
| Pre-Tax Margin | 9.1% | 9.4% | 8.9% | 2.2% | 7.8% |
| Income Tax Expense | 41.3M | 51.6M | 35.3M | 5.6M | 21.5M |
| Net Income | 93.1M | 133M | 139.1M | 35.6M | 116.6M |
| Net Margin | 6.3% | 6.8% | 7.1% | 1.9% | 6.6% |
| EPS (Basic) | 3.78 | 5.37 | 5.60 | 1.43 | 4.69 |
| EPS (Diluted) | 3.75 | 5.32 | 5.56 | 1.42 | 4.67 |
| Weighted Avg Shares | 24.65M | 24.79M | 24.85M | 24.93M | 24.88M |
| Weighted Avg Shares (Diluted) | 24.85M | 24.98M | 25.02M | 25.12M | 24.99M |
Innospec Inc.
NASDAQ:IOSP
Intrinsic Alpha fair value
Locked
Current Price
$78.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.